Upadacitinib Market Report 2026

Upadacitinib Market Overview

• Upadacitinib market size has reached to $1.5 billion in 2025 • Expected to grow to $2.89 billion in 2030 at a compound annual growth rate (CAGR) of 14% • Growth Driver: Rising Incidence Of Autoimmune Diseases Driving Growth In The Market • Market Trend: Advancements In Oral Janus Kinase (JAK) Inhibitors For Autoimmune Disease Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Upadacitinib Market?

Upadacitinib is a Janus kinase (JAK) inhibitor used to treat several inflammatory conditions by targeting and inhibiting specific enzymes involved in the inflammatory process. It is prescribed for moderate to severe rheumatoid arthritis (RA) and other autoimmune diseases. Upadacitinib provides an alternative to traditional disease-modifying anti-rheumatic drugs (DMARDs) and biologics, offering targeted therapy with the convenience of oral administration. The main product types of upadacitinib are Janus kinase inhibitors, antirheumatic agents, and small molecule drugs. Janus kinase (JAK) inhibitors are medications that block the activity of Janus kinase enzymes to reduce inflammation and treat autoimmune diseases. It is applicable in various applications such as rheumatoid arthritis, psoriatic arthritis, and Crohn's disease and is used by several end users, including hospitals, home care, specialty clinics, and others.

What Is The Upadacitinib Market Growth Forecast?

The upadacitinib market size is expected to see rapid growth in the next few years. It will grow to $2.89 billion in 2030 at a compound annual growth rate (CAGR) of 14.0%. The growth in the forecast period can be attributed to increasing clinical approvals for new indications, rising focus on personalized autoimmune treatment, expansion of oral immunotherapy pipelines, growing investments in inflammatory disease research, increasing adoption of advanced small molecule drugs. Major trends in the forecast period include increasing adoption of jak inhibitor therapies, rising preference for oral targeted treatments, growing use of small molecule immunomodulators, expansion of autoimmune disease indications, enhanced focus on long-term disease management.

Global Upadacitinib Market Segmentation

1) By Drug Classes: Janus Kinase Inhibitors, Antirheumatic Agents, Small Molecule Drugs 2) By Application: Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease 3) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users Subsegments: 1) By Janus Kinase Inhibitors: JAK1 Inhibitors, JAK2 Inhibitors, JAK3 Inhibitors, TYK2 Inhibitors 2) By Antirheumatic Agents: Disease-Modifying Antirheumatic Drugs (DMARDs), Biologic DMARDs, Conventional Synthetic DMARDs 3) By Small Molecule Drugs: Oral Small Molecule Drugs, Topical Small Molecule Drugs

What Is The Driver Of The Upadacitinib Market?

The rising incidence of autoimmune diseases is expected to propel the growth of the upadacitinib market going forward. Autoimmune diseases are conditions in which the immune system mistakenly attacks the body's healthy cells, thinking they are foreign invaders. The incidence of autoimmune diseases is driven by genetic predisposition, environmental triggers, and changes in lifestyle and immune system behavior. Upadacitinib helps in autoimmune diseases by targeting and inhibiting JAK1, effectively reducing inflammation and modulating the immune response in conditions such as rheumatoid arthritis and psoriatic arthritis. For instance, in February 2024 according to the Arthritis Australia is a Australia-based non-profit organization In 2025, an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA), with the numbers expected to rise by 2040 to approximately 280,040 males and 479,828 females. Therefore, the rising incidence of autoimmune diseases is driving the growth of the upadacitinib industry.

Key Players In The Global Upadacitinib Market

Major companies operating in the upadacitinib market are AbbVie Inc, Pfizer Inc, Eli Lilly and Company, Incyte Corporation, Novartis AG, GlaxoSmithKline plc, Bristol‑Myers Squibb Company, Sanofi SA, Takeda Pharmaceutical Company Ltd, Astellas Pharma Inc, AstraZeneca PLC, Gilead Sciences Inc, Teva Pharmaceutical Industries Ltd, Mitsubishi Tanabe Pharma Corporation, Kyowa Hakko Kirin Co Ltd, Galapagos NV, UCB SA, Daiichi Sankyo Company Ltd, Horizon Therapeutics plc, Regeneron Pharmaceuticals Inc.

Global Upadacitinib Market Trends and Insights

Major companies operating in the upadacitinib market are focusing on developing innovative products such as oral Janus kinase (JAK) inhibitors to expand treatment options for autoimmune diseases. Oral Janus kinase inhibitors are small-molecule drugs that block Janus kinase enzymes to suppress immune overactivation and inflammation, effectively treating autoimmune and inflammatory diseases. For instance, in April 2023, AbbVie Inc., a US-based pharmaceutical company, announced RINVOQ (upadacitinib), which received European Commission approval for treating moderately to severely active Crohn's disease. This oral formulation allows for once-daily administration, improving convenience and adherence for patients. The oral delivery method provides a quicker onset of action compared to traditional treatments, making it easier for patients to follow their prescribed treatment plans.

What Are Latest Mergers And Acquisitions In The Upadacitinib Market?

In March 2023, AbbVie Inc., a US-based pharmaceutical company, partnered with Lupus Therapeutics for a Phase 3 clinical program involving upadacitinib in systemic lupus erythematosus (SLE). Through this partnership, AbbVie aims to leverage Lupus Therapeutics’ network and expertise for patient recruitment, site activation, and engagement to accelerate evaluation of upadacitinib for an additional autoimmune indication. Lupus Therapeutics LLC is a US-based Company that focuses on accelerating the development of treatments for lupus by managing clinical research and trials.

Regional Outlook

North America was the largest region in the upadacitinib market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Upadacitinib Market?

The upadacitinib market consists of sales of immunosuppressants and anti-inflammatory agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Upadacitinib Market Report 2026?

The upadacitinib market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the upadacitinib industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.